Pharmacy

/Pharmacy

Pharmacy

/Pharmacy

Pharmacy

/Pharmacy

Pharmacy

/Pharmacy

Pharmacy

/Pharmacy

Pharmacy

/Pharmacy

FDA Approves Deflazocort (Emflaza®) To Treat Duchenne Muscular Dystrophy (DMD)

On February 9th, 2017 the U.S. Food and Drug Administration (FDA) approved Emflaza® (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza® is a corticosteroid that works […]

By | February 15th, 2017|Blog, News, Pharmacy|0 Comments

Mounting Problem of Opioid Diversion: Major Emerging Problem for Health Systems in US

PM05The fight against the diversion of opioids and other controlled substances is heating up in the nation’s health systems, according to experts at a packed session at the 2016 annual meeting of the American Society of Consultant Pharmacists (ASCP). Two major factors are providing the wake-up call […]

By | January 17th, 2017|Blog, Pharmacy|0 Comments

Direct Switching From TNF Rheumatoid Arthritis (RA) Drugs Shows Beneficial Effect in Non-Responsive Patients

pci3Rheumatoid arthritis (RA), the most common autoimmune disease, is characterized by persistent synovitis and systemic inflammation. Genetic predisposition as well as autoantibodies and environmental factors, such as smoking, are associated with an increased risk of RA. Traditionally RA has been treated with disease modifying anti-rheumatic drugs (DMARDs) […]

By | November 21st, 2016|Blog, Pharmacy|0 Comments

American Society of Health-System Pharmacists (ASHP) Publishes the First Set of National Guidelines Regarding Controlled Substances Diversion Prevention Guidelines

resize_shutterstock_375027991-convertedOn 10/28/2016 the American Society if Health-System Pharmacists (ASHP) announced the publishing of the first set of national guidelines designed to help healthcare organizations devise and implement strategies to prevent the diversion of controlled substances. The guidelines include a framework for creating a collaborative, comprehensive controlled substances […]

By | November 1st, 2016|Blog, Pharmacy|0 Comments

FDA Warns About Amputation Risk With Canagliflozin (Invokana®)

invokana-pill-boxThe US Food and Drug Administration (FDA) has issued a new safety alert that the diabetes drug canagliflozin (Invokana, Invokamet, Janssen) has been associated with an approximately twofold risk for leg and foot amputations compared with placebo in an ongoing clinical trial. The FDA has not yet […]

By | October 24th, 2016|Blog, Pharmacy|0 Comments

Hospital Data Show Skyrocketing Drug Prices

resize_shutterstock_318429077On October 11th, 2016 it was reported that a new analysis of drug pricing data finds that inpatient hospital drug costs increased more than 38% per admission between 2013 and 2015. Today’s report is based on inpatient drug pricing data, as analyzed by the University of Chicago’s […]

By | October 23rd, 2016|Blog, Pharmacy|0 Comments

FDA Amends List of Drug Products That May Not Be Compounded By Pharmacists

resize_shutterstock_418770058On 10/6/2016, the U.S. Food and Drug Administration issued a final rule amending FDA’s list of drug products that may not be compounded under certain sections of the Food, Drug, and Cosmetic Act (FD&C Act) that allow the marketing of unapproved compounded drugs. Drug products on the […]

By | October 23rd, 2016|Blog, Pharmacy|0 Comments

Long-Acting Opioids Increase Mortality Risk Over Alternative Medications

resize_shutterstock_256514542Long-acting opioid medications are associated with an increased risk for death among patients treated for non-cancer pain in comparison with patients treated with other pain medications, including gabapentin (multiple brands) and cyclic antidepressants, particularly in the first month after starting therapy, the results of a large US […]

By | October 23rd, 2016|Blog, Pharmacy|0 Comments

Fish Oil used with Warfarin Does Not Significantly Affect either the INR or Incidence of Adverse Events in Patients with Atrial Fibrillation and DVT

druginteractionsWarfarin is a leading anticoagulant in the management of atrial fibrillation (AF) and deep vein thrombosis (DVT). Multiple drug interactions influence the safety of routine warfarin use and while extensive literature exists regarding the effect on warfarin control and bleeding incidence with many medicines, there is little […]

By | October 23rd, 2016|Blog, Pharmacy|0 Comments

On-Site Pharmacists Show Value Worth in Mental Health Setting

resize_shutterstock_484138195Patients receiving psychiatric services at community mental health centers (CMHCs) are often prescribed medication that is critical to the treatment of behavioral health conditions, including schizophrenia, bipolar disorder, anxiety, and depression. Previous studies have shown correlation between rates of medication adherence and risk of hospitalization, but potential […]

By | October 23rd, 2016|Blog, Pharmacy|0 Comments